APA (7th ed.) Citation

TV, G., AP, S., KB, K., TN, S., AO, I., KD, G., . . . EN, I. (2021). Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. Hereditary cancer in clinical practice, 19(1), 14. https://doi.org/10.1186/s13053-021-00173-2

Chicago Style (17th ed.) Citation

TV, Gorodnova, et al. "Neoadjuvant Therapy of BRCA1-driven Ovarian Cancer by Combination of Cisplatin, Mitomycin C and Doxorubicin." Hereditary Cancer in Clinical Practice 19, no. 1 (2021): 14. https://doi.org/10.1186/s13053-021-00173-2.

MLA (9th ed.) Citation

TV, Gorodnova, et al. "Neoadjuvant Therapy of BRCA1-driven Ovarian Cancer by Combination of Cisplatin, Mitomycin C and Doxorubicin." Hereditary Cancer in Clinical Practice, vol. 19, no. 1, 2021, p. 14, https://doi.org/10.1186/s13053-021-00173-2.